secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Hawk Acquisition Corp (BKHA)
CIK:        0002000775
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001829126-26-002413
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vesicor Therapeutics appoints Michael Tolentino as CEO; Luo Feng becomes CSO
----------------------------------------------------------------------------

- Michael Tolentino, M.D., appointed CEO of Vesicor Therapeutics, the de-SPAC target of Black Hawk Acquisition (Nasdaq: BKHA, BKHAU, BKHAR), effective March 17, 2026.
- Tolentino succeeds founder Luo Feng, who becomes Chief Scientific Officer; Tolentino brings 20+ years biotech experience including inventing Avastin and co-founding Aviceda ($207.5M Series C).
- Employment agreement: 3-year term, $48k base salary (subject to increase if Vesicor raises $5M), severance of 2x salary plus bonus, non-compete for 1 year post-termination.
- Tolentino aims to accelerate IND-enabling studies and FDA submission for Vesicor's p53-based cancer therapeutics developed with precision-engineered microvesicles.
- Tolentino also serves as co-founder/CEO of Avdarna Therapeutics and co-founder/CDO of Aikium; he previously led Acuity Pharmaceuticals (merged into OPKO Health).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2000775/000182912626002413/0001829126-26-002413-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2000775/000182912626002413/blackhawkacq_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-26-002413

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer